Fasiglifam (TAK-875)
TAK-875_302
Phase 3 small_molecule terminated
Quick answer
Fasiglifam (TAK-875) for Glycemic Control is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Glycemic Control
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated